483
Samsung Biologics Co., Ltd.Samsung Biologics Co., Ltd. – FDA 483, Feb 20, 2023
Record Details
An FDA inspection of Samsung Biologics Co., Ltd. in Yeonsu-gu, Incheon, Republic of Korea, revealed significant deficiencies in their quality control unit, including data integrity violations and incomplete investigations. The inspection also cited issues with the requalification of reference standards and inadequate control over incoming final containers. These findings indicate a lack of robust quality system oversight.
View Company Profile
ID · ddfd6afc-35be-427a-aeee-027047c73e7d
Other documents for Samsung Biologics Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.